clinical trial · NCT05190419
Study to Assess the Efficacy and Safety of Orismilast in Psoriasis
PsoriasisSkin DiseasesOrismilast modified release tabletsPlacebo
brief summary
This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe plaque-type psoriasis. The purpose of the study is to assess the effect of orismilast modified release in moderate-to-severe plaque-type psoriasis and assess the safety aspects of these 3 different doses.The patients will receive an oral treatment of either orismilast modified release tablets or placebo tablets 2 times a day for 16 weeks.
started
Dec 30, 2021
primary completion
Nov 24, 2022
completion
Dec 20, 2022
last updated
Apr 16, 2024
official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate-to-Severe Plaque-Type Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol